ILX-002 / Illexcor Therapeutics - LARVOL DELTA

Direct hemoglobin S polymerization inhibitor MCP435 completely halts ongoing disease pathophysiology in transgenic sickle cell disease mice (ASH 2025) - "MCP435, an analogue of clinical stage drug ILX002, is a potent directpolymerization inhibitor that has demonstrated the ability to impede polymerization kinetics in vitro,increasing both polymerization delay time and saturated solubility (Csat) of deoxygenated HbS...MCP435 achieved functional disease resolution in transgenic SCD mice bypreventing polymerization-mediated RBC damage and normalizing RBC survival. This mechanistic proof-of-concept study demonstrated that reproducing sickle trait–like polymerization kinetics with a directpolymerization inhibitor can halt the pathophysiology of SCD."

Preclinical • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

A Novel Direct Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease – In Vivo Efficacy of Ilx-002 in Humanized Mice (ASH 2024) - "The dramatic disease-modifying effects observed in Townes SS mice at clinically achievable drug levels support ILX-002's potential to significantly improve patient outcomes. These compelling preclinical results warrant rapid advancement of ILX-002 into human trials."

Preclinical • Bone Marrow Transplantation • Gene Therapies • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease (PRNewswire) - "Zynext Ventures USA LLC...announced its investment in Illexcor Therapeutics (Illexcor), a pioneering biopharmaceutical company developing next-generation oral therapies for sickle cell disease (SCD)....Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD. Their lead asset, currently in preclinical development, is designed to bind to Hemoglobin S and effectively block polymerization and sickling, offering the potential for disease-modifying clinical benefits....'We are excited to partner with Zynext Ventures to advance our lead drug ILX002 into clinical trials later this year'."

Licensing / partnership • New trial • Sickle Cell Disease